ATE514690T1 - Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren - Google Patents

Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren

Info

Publication number
ATE514690T1
ATE514690T1 AT05010831T AT05010831T ATE514690T1 AT E514690 T1 ATE514690 T1 AT E514690T1 AT 05010831 T AT05010831 T AT 05010831T AT 05010831 T AT05010831 T AT 05010831T AT E514690 T1 ATE514690 T1 AT E514690T1
Authority
AT
Austria
Prior art keywords
present application
formula
receptors
affinity
group
Prior art date
Application number
AT05010831T
Other languages
English (en)
Inventor
Paolo Lazzari
Stefania Ruiu
Gerard Aime Pinna
Gabriele Murineddu
Original Assignee
Neuroscienze Pharmaness S C A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroscienze Pharmaness S C A R L filed Critical Neuroscienze Pharmaness S C A R L
Application granted granted Critical
Publication of ATE514690T1 publication Critical patent/ATE514690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05010831T 2004-05-24 2005-05-19 Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren ATE514690T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001032A ITMI20041032A1 (it) 2004-05-24 2004-05-24 Compositi farmaceutici

Publications (1)

Publication Number Publication Date
ATE514690T1 true ATE514690T1 (de) 2011-07-15

Family

ID=34936678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05010831T ATE514690T1 (de) 2004-05-24 2005-05-19 Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren

Country Status (7)

Country Link
US (2) US7659407B2 (de)
EP (1) EP1602656B1 (de)
JP (1) JP5111740B2 (de)
AT (1) ATE514690T1 (de)
CA (1) CA2507712A1 (de)
ES (1) ES2368567T3 (de)
IT (1) ITMI20041032A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203845A1 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP5237799B2 (ja) * 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
WO2007131538A1 (en) * 2005-07-15 2007-11-22 Laboratorios Del Dr. Esteve, S.A. Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009709A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Cycloalkane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1849776A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepan- oder Azocan-substituierte Pyrazolinderivate, deren Herstellung und Anwendung als Arzneimittel
EP1849775A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Cycloalkan substituierte Pyrazolin-Verbindungen, ihre Herstellung und Verwendung als Medikamente.
ES2327204B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina octahidropentalensustituidos, su preparacion y su uso como medicamentos.
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1849783A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Octahydropentalen substituierte Pyrazolin-Verbindungen, ihre Herstellung und Verwendung als Medikamente.
EP1951678A1 (de) 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazolverbindungen mit den cannabinoidrezeptor (cb1) antagonisierender wirkung
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
WO2008062424A2 (en) * 2006-07-31 2008-05-29 Cadila Healthcare Limited Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
GB0625196D0 (en) * 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
TWI434686B (zh) * 2008-11-03 2014-04-21 Nat Health Research Institutes 咪唑－４－酮及咪唑－４－硫酮化合物
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
FR2978660B1 (fr) * 2011-08-05 2013-09-20 Oreal Utilisation d'antagoniste du recepteur cb1 en tant qu'agent blanchissant et/ou anti-brunissement des matieres keratiniques
CN108912103A (zh) * 2018-01-21 2018-11-30 吕迎春 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
RU2139281C1 (ru) * 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US6716991B1 (en) * 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
JP2001508799A (ja) 1997-01-21 2001-07-03 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体モジュレータ
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
JP2003512357A (ja) 1999-10-18 2003-04-02 ユニバーシティ オブ コネチカット カンナビノイドレセプタ拮抗物質としてのピラゾール誘導体
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
UA74367C2 (uk) 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
EP1421077A4 (de) 2001-08-31 2004-11-17 Univ Connecticut Neue, auf cannabinoidrezeptoren wirkende pyrazolanaloga
US6836337B2 (en) 2001-09-20 2004-12-28 Visual Pathways, Inc. Non-invasive blood glucose monitoring by interferometry
CN110894196A (zh) * 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7279500B2 (en) * 2002-08-09 2007-10-09 Virginia Commonwealth University Sulfonamide cannabinoid agonists and antagonists
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
DE10239832A1 (de) 2002-08-29 2004-03-18 Lipal Biochemicals AG c/o University of Zurich Sarcolysyl-Derivate und Verfahren zu deren Herstellung
BR0317659A (pt) 2002-12-23 2005-12-06 Aventis Pharma Gmbh Derivados de pirazol como inibidores de fator xa
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
WO2005016877A2 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives

Also Published As

Publication number Publication date
EP1602656A1 (de) 2005-12-07
US20100105896A1 (en) 2010-04-29
CA2507712A1 (en) 2005-11-24
US7659407B2 (en) 2010-02-09
JP2005350458A (ja) 2005-12-22
ES2368567T3 (es) 2011-11-18
US20050261281A1 (en) 2005-11-24
ITMI20041032A1 (it) 2004-08-24
US8227620B2 (en) 2012-07-24
JP5111740B2 (ja) 2013-01-09
EP1602656B1 (de) 2011-06-29

Similar Documents

Publication Publication Date Title
ATE514690T1 (de) Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren
ITMI20041033A1 (it) Composti farmaceutici
DE602004022404D1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
EP1288202A4 (de) N-acyltetrahydroisochinolin-derivate
KR960704919A (ko) 신규인 펩티드 유도체 (novel peptide derivative)
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
WO2008093831A1 (ja) ブロック共重合体並びにそれを用いた組成物、液状組成物、発光性薄膜及び高分子発光素子
EA200702002A1 (ru) Замещённые производные пиразолилоксифенила, применяемые в качестве гербицидов
ATE532834T1 (de) Pigmentdispersion und tintenzusammensetzung, die diese verwendet
ATE514730T1 (de) Polykarbonatharz und verfahren zu seiner herstellung
DE69808282D1 (de) Verwendung von Thienopyrimidinen als Fungizide
TW200720399A (en) Light-emitting element and iridium complex
TW200637559A (en) 3-propenylcefem derivative
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
HRP20050628A2 (en) Substituted benzoyl derivatives uses as herbicides
MX2024008480A (es) Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2).
TR200102572T2 (tr) Eritromisin türevleri.
BRPI0506927A (pt) compostos orgánicos
TW200607828A (en) Polymer, polymer film and polymer film device using same
MXPA05010651A (es) Compuestos de pirazol.
EP1632484A4 (de) Thiadiazolinderivat
BRPI0511250A (pt) composto de tiazol e uso deste
MXPA05010650A (es) Pirazoles sustituidos.
TW200631960A (en) Organic bismuth compound, preparing method thereof, living radical polymerization initiator, polymer preparation and polymer using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties